Invega Review Shows FDAers At Odds Over Safety Issues With Risperdal Follow-On
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA review documents illustrate internal disagreement at the division level during the agency’s review of Johnson & Johnson’s schizophrenia agent Invega. The review also highlights the difficulty in assessing safety in the unique patient population affected by schizophrenia.